PODCAST

Healthcare Policy

ReachMD

science & medicine medicine

All Episodes

00:00:00

Reforming the FDA's Drug Approval Process

Healthcare Policy ·

2009/02/23

Host: Jack Lewin, MD Guest: Mark McClellan, MD, PhD It takes a substantial measure of time, money and manpower to bring a new drug from the bench to the marketplace. One key aspect of this sequence is the drug approval process, overseen by the Food and Drug Administration (FDA). Host Dr. Jack Lewin welcomes Dr. Mark McClellan, director of the Engelberg Center for Health Care Reform at the Brookings Institution, former commissioner of the FDA and administrator of the Centers for

00:00:00

How the Economy Affects Medicine and Healthcare Reform

Healthcare Policy ·

2009/02/23

Guest: Thomas Lee, MD, MSc Host: Martin Samuels, MD What change can we realistically expect of the national healthcare delivery system, given the existing institutions and agendas, the economy and the current presidential administration? Will the practice of medicine fundamentally change? To discuss these and other topics, host Dr. Martin A. Samuels welcomes Dr. Thomas H. Lee. Dr. Lee is an internist, cardiologist, and CEO of Partners Community HealthCare, Inc., founded by Brigham

00:00:00

Treatments for Pancreatic and Colorectal Cancers

Healthcare Policy ·

2009/02/11

Guest: J. Randolph Hecht, MD Host: Jay Goldstein, MD How have treatments for colorectal and pancreatic cancers advanced in recent years, and are novel treatments reducing the mortality rate of patients with these cancers? Dr. J. Randolph Hecht, director of the GI Oncology Program at theUCLA Health Systemand clinical professor of medicine in the hematology-oncology division at the UCLA David Geffen School of Medicine, looks at some of the newer pharmacological agents and methods

00:00:00

A Way to Boost Cancer Cell Vulnerability to Chemotherapy

Healthcare Policy ·

2009/02/11

Guest: John Docherty Host: Bruce Japsen Cancer cells can be made to become more vulnerable to treatments like chemotherapy, and there are therapeutics under development which are designed to impact this so-called microenvironment of tumor cells. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about a new wave of treatments and therapies in the biotechnology industry that could better target cancer cells and in turn help patients deal with the side

00:00:00

Cardiac Screening for Children Prescribed ADHD Meds?

Healthcare Policy ·

2009/02/09

Guest: Patrick Frias, MD Host: Jennifer Shu, MD, FAAP Although sudden death in the pediatric population is rare, there has been a great deal of discussion recently over the possibility of an increase in risk of sudden cardiac death among individuals taking stimulant medication for attention-deficit hyperactivity disorder (ADHD). Dr. Patrick Frias, a pediatric cardiologist and electrophysiologist at Sibley Heart Center Cardiology in Atlanta and associate professor of pediatrics at

00:00:00

The Evolution of Clinical Pharmacy Practice

Healthcare Policy ·

2009/02/05

Guest: William Zellmer, MPH Host: Charles Turck, PharmD, BCPS, BCCCP Clinical pharmacy became a part of the modern medical lexicon in the 1960s, with pharmacy schools and pharmacists making an effort to become more patient-centered. From the role of the pharmacist in patient service, to the influence of technology in pharmacy practice, to the way our patients view our profession, how have things changed for the better? William Zellmer, former deputy executive vice president for the

00:00:00

Lethal Injection as Capital Punishment: The Issues

Healthcare Policy ·

2009/02/05

Guest: Frank Romanelli, PharmD, MPH Host: Charles Turck, PharmD, BCPS, BCCCP Much of the debate surrounding lethal injection and its role as a form capital punishment in the United States stems from concerns of whether the drug combinations we choose-and how we administer them-engender a degree of unnecessary suffering. When weighing the ethics of lethal injection against the need for criminal justice, and even considering the legality of the participation of health care

00:00:00

Combination Therapy to Manage Lipids

Healthcare Policy ·

2009/01/27

Guest: James Stolzenbach, MD Host: Bruce Japsen Despite the wide adoption of statins that are practically in the U.S. drinking water, there are still Americans who are notbeing treated with lipid-lowering therapies. So what's the answer?Dr.James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells the Chicago Tribune's Bruce Japsen about combination therapies and other new drugs being pursued by the

00:00:00

Beyond LDL: New Treatment Options to Manage Lipids

Healthcare Policy ·

2009/01/27

Guest: James Stolzenbach, MD Host: Bruce Japsen Consumers and their doctors all know about LDL and the need to lower the so-called bad cholesterol. But what about the treatments beyond those that lower LDL? James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells host Bruce Japsen about new developments in treating and managing cholesterol beyond lowering LDL.

00:00:00

Can Viagra Protect the Heart?

Healthcare Policy ·

2009/01/22

Guest: David Kass, MD Host: Larry Kaskel, MD The medication Viagra has been shown to have positive impact on the heart in recent research. Host Dr. Larry Kaskel discusses with Dr. David Kass,the Abraham and Virginia Weiss Professor of Cardiology and professor of biomedical engineering at Johns Hopkins University, the history of Viagra as a medicine developed for the heart. Dr. David Kass explains the results of his research with mice and how sildenafil triggers an important heart

00:00:00

Extraesophageal GERD: Fact or Fiction?

Healthcare Policy ·

2009/01/19

Guest: John Inadomi, MD Host: Jay Goldstein, MD Non-cardiac chest pain and chronic cough are just two of theextraesophagealmanifestations of gastroesophageal reflux disease, or GERD. What other symptoms should we look for? If a patient displays characteristics of GERD, such as esophogeal regurgitation, is that patient also likely to experience extraesophogeal manifestations of GERD? Dr. John Inadomi, the Dean M. Craig Endowed Chair in Gastrointestinal Medicine at the University of

00:00:00

Selecting the Right Medication for Hypertension in...

Healthcare Policy ·

2009/01/09

Guest: Michael Bresler Host: Shira Johnson, MD There are many vasoactive medications available to treat hypertension in an acute setting. Join Dr. Michael Bresler, professor in the division of emergency medicine at StanfordUniversity School of Medicine and director of Emergency Medicine at the Mills-Peninsula Health System, to discuss the potent arsenal of acute care medications at your disposal. Dr. Shira Johnson is the host for this informative session on the use and misuse of

00:00:00

Drug-Induced Liver Injury

Healthcare Policy ·

2008/12/16

Host: Mark DeLegge, MD Guest: Rowen Zetterman, MD Acetaminophen, vitamin supplements and antibiotics are just a few of the medications that can cause liver injury. What are the signs of drug-induced liver injury? Are the effects immediate, or do the effects become noticeable after an extended period of time? Dr. Rowen Zetterman, professor of internal medicine at the University of Nebraska Medical Center, provides an overview of factors that might lead to drug-induced liver injury

00:00:00

How Do We Manage Medications in Elderly Populations?

Healthcare Policy ·

2008/12/16

Guest: Matthew Wayne, MD, CMD Host: Eric Tangalos, MD What risks does polypharmacy pose for elderly patients, and how should physicians manage medications in the population of their patients over age 65? Dr. Matthew Wayne, assistant professor of medicine at University Hospitals Case Medical Center in Cleveland, discusses the typical symptoms that might indicate an adverse drug reaction, and suggests ways physicians can recognize these symptoms. What factors should physicians keep

00:00:00

State of the Art in Pharmacologic Treatment for...

Healthcare Policy ·

2008/12/11

Guest: Samuel Gandy, MD Host: Lee Freedman, MD What medications are approved for the treatment of Alzheimer's disease? Dr. Samuel Gandy, professor and director of the Farber institute for neurosciences at Thomas Jefferson University, discusses state of the art pharmacologic treatments for Alzheimer's disease with host Dr. Lee Freedman. What are the benefits to each medication, and how can physicians prevent side effects from these medications? How do diet and lifestyle influence

00:00:00

Can Diuretics Prevent Heart Failure?

Healthcare Policy ·

2008/12/09

Guest: Barry Davis, MD, PhD Host: Matthew J. Sorrentino, MD, FACC, FASH Hypertension is the most common underlying risk factor for the development of congestive heart failure. Dr. Barry Davis, the Guy S. Parcel Chair in Public Health and director of the Coordinating Center for Clinical Trials at the University of Texas School of Public Health in Houston, will review a recent analysis of the ALLHAT hypertension trial showing that diuretics significantly reduced the occurrence of

00:00:00

Modernizing Drug Evaluation To Bring Faster Translation

Healthcare Policy ·

2008/11/24

Guest: Scott Riccio Host: Bruce Bloom, DDS, JD Guest: Scott Gottlieb, MD While new science continues to evolve the development of drugs and cures, the scientific principals we use to evaluate the drugs is arguably obsolete. Host Dr. Bruce Bloom is joined in this segment by Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, and Dr. Scott Gottlieb, a

00:00:00

Antiplatelet Therapy After Drug-Eluting Stent...

Healthcare Policy ·

2008/11/24

Host: Doug Weaver, MD Guest: Peter Berger, MD It is no longer a question of whether antiplatelet therapy should be used following implantation of a drug-eluting stent, but rather to what extent and to what duration. With this in mind, many new challenges arise, from bleeding risks to drug intolerance and product cost. Host Dr. Doug Weaver welcomes Dr. Peter Berger, associate chief research officer and director of the Center for Clinical Studies at the Geisinger Clinic in central

00:00:00

Minimally Invasive Spinal Surgery

Healthcare Policy ·

2008/11/20

Guest: Paul Holman, MD Host: Mark Nolan Hill, MD Many of our patients who suffer from significant back pain put off surgery as long as they can, relying primarily on medical and physical therapy while hoping to avoid an elaborate operative procedure. Yet as with so many areas of medicine today, minimally invasive techniques are providing new options for patients with back pain, and others who face spine surgery. As with all new procedures, we have to ask, What are the fundamental

00:00:00

Shifts in Crohn's Disease Treatment Models

Healthcare Policy ·

2008/11/18

Host: Mark DeLegge, MD Guest: William J. Sandborn, MD The current treatment paradigm for Crohn's disease is a pyramid approach, where patients are given the safest medications before pursuing more aggressive strategies. New evidence suggests that Crohn's disease should be treated with the most effective medications first, such as anti-TNF therapies. But is a top-down strategy safe enough for most patients? Dr. William Sandborn, professor of medicine and gastrointestinal research at

323 results

Healthcare Policy

All Episodes

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事